Halozyme Therapeutics shares traded higher Tuesday, March 31, 2026, extending gains as the market focused on recent investor-conference commentary emphasizing continued momentum in subcutaneous drug delivery and a royalty stream expected to exceed $1 billion in 2026. Company remarks from mid-March conference appearances reiterated the 2026 revenue framework around $1.71–$1.81 billion, reinforcing the view that the royalty engine remains the core driver of near-term upside. (ng.investing.com)

Recent conference updates underscored management’s expectation that Halozyme can meaningfully expand the number of commercialized and development-stage products leveraging its delivery technologies over the next few years, a message that tends to support valuation when the broader biotech tape is stable. Investors have been leaning into the multi-year setup in which newer launches contribute more meaningfully beyond 2025, while the broader partner portfolio drives recurring royalty growth. (ng.investing.com)

Separately, Halozyme’s appointment of David Ramsay as interim chief financial officer, effective March 23, 2026, has remained an active talking point as investors look for continuity in capital allocation, guidance execution, and partner economics. The interim appointment followed the previously disclosed CFO transition timing, and the market often treats a clear interim plan as a de-risking factor versus an open-ended leadership gap. (stocktitan.net)

Investors will be monitoring for incremental partner/program updates that could pull forward royalty growth, as well as any meaningful developments in Halozyme’s ongoing IP disputes that could influence the long-run economics of its delivery platform. Near term, trading may continue to react to conference read-throughs, analyst note flow, and any new filings that clarify strategy, costs, or capital return plans. (stocktitan.net)